• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Product › Details

virostatic agent

	Next higher product group	anti-infective drug
	Status	1998-01-01 sales existent

Record changed: 2022-03-03

Advertisement

More documents for virostatic agent

• [1] Abivax S.A.. (9/2/22). "Press Release: Abivax Announces Successful Oversubscribed EUR 49.2M Cross-over Financing with Top-tier US and European Biotech Investors [not for US]". Paris....
• [2] Kinarus Therapeutics Holding AG. (8/22/22). "Press Release: Kinarus Announces the Issuance of Convertible Notes of up to CHF 20 Million to an Entity Managed by Yorkville [ not for any jurisdiction where unlawful]". Basel....
• [3] Synklino ApS. (6/8/22). "Press Release: Synklino Completes Series A Raise of EUR 29.8 Million to Advance Clinical Trials of Its Drug Candidate for the Treatment of Cytomegalovirus (CMV)". Copenhagen....
• [4] ReViral Ltd.. (4/7/22). "Press Release: Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates". New York, NY, London & Research Triangle Park, NC....
• [5] Meletios Therapeutics S.A.S.. (2/28/22). "Press Release: Meletios Therapeutics Signs an Exclusive License Agreement with the Institut Pasteur for the Development of a New Class of Antivirals". Paris....
• [6] AiCuris Anti-infective Cures AG. (2/9/22). "Press Release: AiCuris and Hybridize Therapeutics Enter Worldwide License Agreement of up to €100M for a Direct-acting RNA-based Therapy against BK Virus". Wuppertal & Leiden....
• [7] Leyden Laboratories B.V.. (1/25/22). "Press Release: Leyden Labs Raises $200M in 2021 for a New Approach to Combat Viruses". Amsterdam & Boston, MA....
• [8] Marinomed Biotech AG. (1/21/22). "Press Release: Marinomed Announces the Appointment of Dr. Cornelia Kutzer as Chief Business Officer". Korneuburg....
• [9] Pneumagen Ltd.. (1/19/22). "Press Release: Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)". St Andrew...
• [10] Leyden Laboratories B.V.. (1/18/22). "Press Release: Leyden Labs Licenses Pan-Influenza Antibody from Janssen". Amsterdam & Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2022. Made in Germany.